Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 7 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 2 |
| Substance Abuse Therapeutics Market to 2018 - Introduction | 12 | 2 |
| Overview | 12 | 2 |
| Substance Abuse Therapeutics Market to 2018 - Market Overview | 14 | 8 |
| Introduction | 14 | 1 |
| Revenue Forecasts for Substance Abuse Therapeutics Market | 14 | 1 |
| Revenue | 14 | 2 |
| Annual Cost of Treatment | 16 | 1 |
| Treatment Usage Patterns | 17 | 1 |
| Diseased Population | 17 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 19 | 1 |
| Drivers and Barriers for Substance Abuse Therapeutics Market | 20 | 1 |
| Drivers | 20 | 1 |
| Government Awareness Campaigns are Helping to Increase Awareness of Addiction | 20 | 1 |
| Increasing Prescription Rate | 20 | 1 |
| Barriers | 21 | 1 |
| Compliance in all Conditions Remains an Issue | 21 | 1 |
| Low Treatment Seeking Rate | 21 | 1 |
| Patent Expiries | 21 | 1 |
| Lack of Promising Pipeline Products | 21 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Geographical Landscape | 22 | 16 |
| The US | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Treatment | 23 | 1 |
| Treatment Usage Patterns | 24 | 1 |
| Diseased Population | 24 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 26 | 1 |
| Top Five Countries of Europe | 27 | 1 |
| Revenue | 27 | 1 |
| Annual Cost of Treatment | 28 | 1 |
| Treatment Usage Patterns | 29 | 1 |
| Diseased Population | 29 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 31 | 1 |
| Japan | 32 | 1 |
| Revenue | 32 | 2 |
| Annual Cost of Treatment | 34 | 1 |
| Treatment Usage Patterns | 35 | 1 |
| Diseased Population | 35 | 1 |
| Diagnosed Population | 36 | 1 |
| Prescription Population | 37 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Nicotine Addiction Therapeutics Market | 38 | 12 |
| Introduction | 38 | 1 |
| Treatment Flow Algorithm | 39 | 1 |
| Opportunities/Unmet Needs | 39 | 1 |
| Revenue | 40 | 2 |
| Annual Cost of Treatment | 42 | 1 |
| Treatment Usage Patterns | 43 | 1 |
| Diseased Population | 43 | 1 |
| Diagnosed Population | 44 | 1 |
| Prescription Population | 45 | 1 |
| Drivers and Barriers for the Nicotine Addiction Market | 46 | 1 |
| Drivers | 46 | 1 |
| Increase in Anti-smoking Legislation Across the Nation | 46 | 1 |
| Emergence of Nicotine Addiction Vaccine and Market Growth | 47 | 1 |
| Emergence of More Efficacious Treatment | 47 | 1 |
| Government Programs Encourage Patients to Quit Smoking and Assist in Providing Access to Therapy | 47 | 1 |
| Barriers | 47 | 1 |
| Increase Usage of e-cigarettes | 47 | 1 |
| Failure of Promising Pipeline Products in the Late Stage Trial | 47 | 1 |
| Marketed Products | 48 | 1 |
| Chantix (varenicline) | 48 | 1 |
| Overview | 48 | 1 |
| Zyban (buproprion hydrochloride) | 48 | 1 |
| Overview | 48 | 1 |
| Nicotine Replacement Therapies | 48 | 1 |
| Nicorette | 48 | 1 |
| Nicotrol | 48 | 1 |
| NicoDerm | 49 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Alcohol Dependence Therapeutics Market | 50 | 11 |
| Introduction | 50 | 1 |
| Treatment Flow | 51 | 1 |
| Opportunities/Unmet Needs | 52 | 1 |
| Revenue | 52 | 1 |
| Geographical Segmentation | 53 | 1 |
| Annual Cost of Treatment | 54 | 1 |
| Treatment Usage Patterns | 55 | 1 |
| Diseased Population | 55 | 1 |
| Diagnosed Population | 56 | 1 |
| Prescription Population | 57 | 1 |
| Drivers and Barriers for Alcohol Dependence Therapeutic Market | 58 | 1 |
| Drivers | 58 | 1 |
| Increase in Prescription Rate | 58 | 1 |
| Government Control Strategies to Limit Access to Alcohol will not have a Large Effect on Dependence | 58 | 1 |
| Barriers | 59 | 1 |
| Technical Challenges | 59 | 1 |
| Relapse is Common | 59 | 1 |
| Treatment Seeking Rate is Low | 59 | 1 |
| Marketed Products | 59 | 1 |
| Detoxification treatment options | 59 | 1 |
| Overview | 59 | 1 |
| Campral (acamprosate calcium) | 59 | 1 |
| Overview | 59 | 1 |
| Antabuse (disulfurum) | 60 | 1 |
| Overview | 60 | 1 |
| Vivitrol (naltrexone) | 60 | 1 |
| Overview | 60 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Drug Abuse Therapeutics Market | 61 | 11 |
| Introduction | 61 | 1 |
| Opioid Abuse | 61 | 1 |
| Overview | 61 | 1 |
| Cocaine Abuse | 62 | 1 |
| Overview | 62 | 1 |
| Treatment Flow Algorithm | 62 | 1 |
| Opioid Abuse | 62 | 1 |
| Opportunities/Unmet Needs | 63 | 1 |
| Revenues | 63 | 2 |
| Annual Cost of Therapy | 65 | 1 |
| Treatment Usage Patterns | 66 | 1 |
| Diseased Population | 66 | 1 |
| Diagnosed Population | 67 | 1 |
| Prescription Population | 68 | 1 |
| Drivers and Barriers for Drug Abuse | 69 | 1 |
| Drivers | 69 | 1 |
| Number of Patients Accessing Treatment, Especially in US, will Drive Growth | 69 | 1 |
| New Drugs and High Cost of Therapies Will Drive Revenues | 69 | 1 |
| Barriers | 69 | 1 |
| Lack of Innovative Products in the Pipeline for Drug Abuse | 69 | 1 |
| Marketed Drugs - Opioid Abuse | 70 | 1 |
| Methadone | 70 | 1 |
| Suboxone (buprenorphine and naloxone) | 70 | 1 |
| Buprenorphine Hydrochloride | 70 | 1 |
| Vivitrol (naltrexone) | 70 | 1 |
| Marketed Products - Cocaine Abuse | 70 | 1 |
| Overview | 70 | 1 |
| Sabril (vigabatrin) | 70 | 1 |
| Fluoxetine | 71 | 1 |
| Disulfiram (Antabuse) | 71 | 1 |
| Naltrexone | 71 | 1 |
| Topiramate | 71 | 1 |
| Amantadine | 71 | 1 |
| Baclofen | 71 | 1 |
| Modafinil | 71 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Product Pipeline Analysis | 72 | 5 |
| R&D Pipeline - Nicotine Addiction Therapeutics Market | 72 | 1 |
| Pre-clinical and Discovery Phase | 72 | 1 |
| Phase I | 72 | 1 |
| Phase II | 72 | 1 |
| Promising Pipeline Molecules | 72 | 1 |
| TA-NIC | 72 | 1 |
| Overview | 72 | 1 |
| R&D Pipeline - Alcohol Dependence Therapeutics Market | 73 | 1 |
| Pre-clinical and Discovery Phase | 73 | 1 |
| Phase I | 73 | 1 |
| Phase II | 73 | 1 |
| NDA Filed | 73 | 1 |
| Promising Molecules in the Pipeline | 74 | 1 |
| Selincro | 74 | 1 |
| Overview | 74 | 1 |
| NS11 | 74 | 1 |
| Overview | 74 | 1 |
| R&D Pipeline - Drug Abuse Therapeutics Market | 75 | 1 |
| Pre-clinical and Discovery Phase | 75 | 1 |
| Phase I | 75 | 1 |
| Phase II | 75 | 1 |
| Phase III | 75 | 1 |
| Promising Molecules in the Pipeline | 76 | 1 |
| Sevre-Long | 76 | 1 |
| Overview | 76 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Competitive Landscape | 77 | 8 |
| GlaxoSmithKline | 77 | 1 |
| Overview | 77 | 1 |
| Major Products in the Substance Abuse Therapeutics Market | 77 | 1 |
| Zyban (bupropion hydrochloride) | 77 | 1 |
| Nicorette (nicotine) | 77 | 1 |
| SWOT Analysis | 78 | 1 |
| Pfizer | 78 | 1 |
| Overview | 78 | 1 |
| Major Products in the Substance Abuse Therapeutics Market | 78 | 1 |
| Chantix/Champix (varenicline tartrate) | 78 | 1 |
| Nicotrol | 79 | 1 |
| SWOT Analysis | 79 | 1 |
| Alkermes | 80 | 1 |
| Overview | 80 | 1 |
| Major Products in the Substance Abuse Therapeutics Market | 80 | 1 |
| Vivitrol (naltrexone) | 80 | 1 |
| SWOT Analysis | 80 | 1 |
| Forest Laboratories, Inc. | 81 | 1 |
| Overview | 81 | 1 |
| Major Products in the Substance Abuse Therapeutics Market | 81 | 1 |
| Campral (acamprosate) | 81 | 1 |
| SWOT Analysis | 81 | 1 |
| Teva Pharmaceuticals | 82 | 1 |
| Overview | 82 | 1 |
| Major Products in the Substance Abuse Therapeutics Market | 82 | 1 |
| Antabuse (disulfiram) | 82 | 1 |
| SWOT Analysis | 82 | 1 |
| Reckitt Benckiser Pharmaceuticals | 83 | 1 |
| Overview | 83 | 1 |
| Major Products in the Substance Abuse Therapeutics Market | 83 | 1 |
| Suboxone (buprenorphine and naloxone) | 83 | 1 |
| Subutex | 83 | 1 |
| SWOT Analysis | 84 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Strategic Consolidations | 85 | 5 |
| Mergers and Acquisitions (M&A) | 85 | 1 |
| Deals by Year | 85 | 1 |
| Deals by Geography | 86 | 1 |
| Major Mergers and Acquisitions, 2007-2012 | 86 | 1 |
| Reckitt Benckiser Acquires Rights to Narcotic Addition Treatments from Merck in March 2010 | 86 | 1 |
| Biotie Therapies Acquires Synosia Therapeutics in February 2011 | 86 | 1 |
| Alkermes Completes Merger with Elan Drug Technologies in September 2011 | 87 | 1 |
| Licensing Agreements | 87 | 1 |
| Deals by Year | 87 | 1 |
| Deals by Geography | 88 | 1 |
| Major Licensing and Co-Development Agreements, 2007-2012 | 88 | 1 |
| GlaxoSmithKline Terminates its Co-Development Agreement with Targacept in May 2011 | 88 | 1 |
| Cypress Bioscience Enters into Licensing Agreement with Alexza Pharmaceuticals in August 2010 | 89 | 1 |
| Substance Abuse Therapeutics Market to 2018 - Appendix | 90 | 8 |
| Market Definitions | 90 | 1 |
| Abbreviations | 90 | 1 |
| Bibliography | 91 | 2 |
| Research Methodology | 93 | 1 |
| Coverage | 93 | 1 |
| Secondary Research | 93 | 1 |
| Primary Research | 93 | 1 |
| Therapeutic Landscape | 94 | 3 |
| Epidemiology-based Forecasting | 94 | 2 |
| Market Size by Geography | 96 | 1 |
| Geographical Landscape | 97 | 1 |
| Pipeline Analysis | 97 | 1 |
| Competitive Landscape | 97 | 1 |
| Expert Panel Validation | 97 | 1 |
| Contact Us | 97 | 1 |
| Disclaimer | 97 | 1 |
